Product Images Flovent Hfa

This text represents a table or chart showing the results of the drug FLOVENT HFA, which was taken twice daily at a dose of 88 mcg, in increasing the Forced Expiratory Volume (FEV) of patients. The table indicates that measurements were taken at T1 through T12 time points, with the endpoint being at T12, and a placebo control was used to compare the results. Due to the lack of understandable data, the actual results cannot be extrapolated from this text.*

This appears to be a chart or graph showing the change in FEV (forced expiratory volume) from baseline for various treatment options. The treatments mentioned are a placebo, FLOVENT HFA at 88mcg twice daily, 220mcg twice daily, and 440mcg twice daily. The change in FEV is shown to be around 9%, but without more context, it is difficult to assess what this indicates.*

The text is showing a graph with different percentages of subjects and the reduction in dose with the increase in dose for two different medications - Placebo and FLOVENT HFA. The percentages are not completely clear, but they range from 3% to 60%.*

The description of the product is a metal canister with a dark orange plastic actuator and a mouthpiece. It also includes a counter peach cap.*

The text is a list of words and does not provide enough context to generate a useful description.*

This text provides a short instruction on how to exhale deeply by releasing as much air as possible from the lungs.*

The text is not clear and contains only a few short phrases. Therefore, the description cannot be generated.*

This is a medication with NDC code 0173-0718-20 containing fluticasone propionate in an inhalation aerosol form. It is intended for oral inhalation and should only be used with the FLOVENT HFA actuator. The package contains a patient information leaflet that should be dispensed with the inhaler. Dosage information can be found in the prescribing information. The medication's net weight is 10.6 g and it has 120 metered actuations.*

This text describes a medication called "Flovent HFA," which is an inhaler containing "fluticasone propionate" used for oral inhalation. The medication is intended to be used with the "FLOVENT HFA actuator only." The text instructs pharmacists to detach the "Patient Information leaflet" from the package insert and dispense it with the inhaler. Dosage information can be found in the prescribing information. The medication weighs 12 grams and contains 120 metered actuations.*

This is a medication called Flovent HFA, which contains fluticasone propionate and is designed for oral inhalation with a specific type of actuator. The packaging includes a Patient Information leaflet that should be detached and given to the patient along with the inhaler. The prescribing information should be referred to for details about dosage. The product has a weight of 12 g and provides 120 metered actuations.*